Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacogenomics
• Hematology

Background:

• Race is an independent risk factor for poor prognosis in coronary artery disease (CAD).
• Race-related disparities exist in CAD patient presentation, comorbidities, socioeconomic status, and treatment.
• Genetically driven differences in medication response contribute to racial disparities in cardiovascular care.

Purpose of the Study:

• To review genotypic and phenotypic race-related differences in platelet reactivity.
• To examine race-related variations in response to antiplatelet therapy in cardiovascular patients.
• To emphasize the need for targeted antithrombotic strategies.

Main Methods:

• Literature review focusing on studies investigating race, platelet reactivity, and antiplatelet therapy response.
• Analysis of genotypic and phenotypic data related to racial differences in platelet function.
• Synthesis of evidence on the impact of these differences on cardiovascular outcomes.

Main Results:

• Significant race-related differences in platelet reactivity and response to antiplatelet agents are documented.
• Genetic variations contribute to these disparities, affecting drug efficacy.
• These variations may partially explain worse outcomes observed in specific racial groups with acute coronary syndromes.

Conclusions:

• Race-related variations in platelet reactivity and antiplatelet response necessitate personalized antithrombotic strategies.
• Further research into pharmacogenomics can help optimize antiplatelet therapy for diverse populations.
• Developing targeted treatments is crucial for improving CAD outcomes across all racial groups.